Skip to main content

Moderna, Inc. RSV revenue

  • MRNA · Nasdaq
  • Biotechnology
  • S&P 500
$223.37−3.45%Close 13 Nov 2026 · Market value $87.52B

RSV revenue at Moderna, Inc. came to $29.0M for the quarter to 30 Sep 2026, up 1350.0% from a year earlier.

As Moderna, Inc. reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 6 Nov 2026.

By quarter

$0Sep 2023$0Mar 2024$0Jun 2024$10.0MSep 2024$2.0MMar 2025$0Jun 2025$2.0MSep 2025$7.0MMar 2026$3.0MJun 2026$29.0MSep 2026
Moderna, Inc. RSV revenue, every reported period
Period endingRSV revenueChange on a yearFiled
30 Sep 2026$29.0Mup 1350.0%6 Nov 2026
30 Jun 2026$3.0M—31 Jul 2026
31 Mar 2026$7.0Mup 250.0%1 May 2026
30 Sep 2025$2.0Mdown 80.0%6 Nov 2025
30 Jun 2025$0—1 Aug 2025
31 Mar 2025$2.0M—1 May 2025
30 Sep 2024$10.0M—7 Nov 2024
30 Jun 2024$0—1 Aug 2024
31 Mar 2024$0—2 May 2024
30 Sep 2023$0—3 Nov 2023

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Moderna, Inc.: COVID revenue · Stand-ready manufacturing revenue · Collaboration Arrangement, Including Arrangements With Affiliate revenue · Grant revenue · United States revenue · Rest of world revenue · Europe revenue · financial statements

Every KPI and segment of MRNA, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.